8.66
7.71%
0.62
アフターアワーズ:
8.60
-0.06
-0.69%
前日終値:
$8.04
開ける:
$7.96
24時間の取引高:
77,726
Relative Volume:
1.33
時価総額:
$29.02M
収益:
$15.53M
当期純損益:
$-87.68M
株価収益率:
-4.534
EPS:
-1.91
ネットキャッシュフロー:
$-79.02M
1週間 パフォーマンス:
+6.91%
1か月 パフォーマンス:
-31.70%
6か月 パフォーマンス:
-64.65%
1年 パフォーマンス:
-53.63%
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-01-06 | アップグレード | Jefferies | Hold → Buy |
2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
2021-09-09 | 開始されました | SVB Leerink | Outperform |
2021-05-17 | 再開されました | Piper Sandler | Overweight |
2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
2020-11-10 | 開始されました | JP Morgan | Overweight |
2020-11-10 | 開始されました | Jefferies | Buy |
2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - MarketBeat
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - StockTitan
(ALGS) Investment Analysis and Advice - Stock Traders Daily
Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com
Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Canada
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aligos Therapeutics names new chief medical officer - Investing.com
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - StockTitan
Aligos Therapeutics stock hits 52-week low at $8.5 - Investing.com
Aligos Therapeutics stock hits 52-week low at $8.5 By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - Defense World
Aligos Therapeutics' (ALGS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World
Market Recap Check: Aligos Therapeutics Inc (ALGS)’s Negative Finish at 10.18, Up/Down -28.11 - The Dwinnex
Aligos Phase II results for ALG-055009 in MASH fail to impress - The Pharma Letter
Aligos shares maintain Buy rating with price target after study - Investing.com
Aligos reports positive data from Phase IIa MASH treatment trial - Clinical Trials Arena
Aligos reports progress in MASH treatment study - Investing.com
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - Markets Insider
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - MarketBeat
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - ForexTV.com
Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear - Scrip
How will Aligos Therapeutics Inc’s (ALGS) earnings compare to estimates this quarter? - US Post News
Hark, Herald MASH phase II positive but Aligos THRown for a loop - BioWorld Online
Aligos reports progress in MASH treatment study - Investing.com India
Aligos stock falls on data for MASH candidate (NASDAQ:ALGS) - Seeking Alpha
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - 新浪香港
Aligos' fatty liver disease treatment meets main goal in mid-stage study - Reuters
Aligos Therapeutics Announces Positive Topline Results from - GlobeNewswire
Aligos Therapeutics Inc. (ALGS) Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - StreetInsider.com
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - StockTitan
Aligos Therapeutics to unveil Phase 2a study results By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Trading 3.5% Higher - MarketBeat
Aligos Therapeutics to unveil Phase 2a study results - Investing.com
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - ForexTV.com
Aligos Therapeutics to unveil Phase 2a study results By Investing.com - Investing.com UK
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - StockTitan
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 3.5% - Defense World
Zura Bio (NASDAQ:ZURA) versus Aligos Therapeutics (NASDAQ:ALGS) Critical Comparison - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 18.3% in August - Defense World
Liver Diseases Therapeutics Market Outlook Through 2024-2033 - WhaTech
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 18.3% in August - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 12.3% - MarketBeat
Piper Sandler keeps Aligos shares at Overweight rating with consistent price target - Investing.com
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):